DexCom (NASDAQ:DXCM) Receiving Somewhat Favorable Media Coverage, Study Shows

Media coverage about DexCom (NASDAQ:DXCM) has been trending somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DexCom earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 45.2493485346263 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have impacted Accern’s analysis:

Shares of DexCom (NASDAQ DXCM) traded down $1.19 on Friday, hitting $57.04. The stock had a trading volume of 1,365,832 shares, compared to its average volume of 1,456,392. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

DXCM has been the topic of several recent research reports. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reiterated a “buy” rating and issued a $76.00 price objective on shares of DexCom in a research note on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and issued a $79.00 price objective on shares of DexCom in a research note on Sunday, September 10th. Finally, Barclays assumed coverage on shares of DexCom in a research note on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $71.36.

In related news, EVP Andrew K. Balo sold 6,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total value of $389,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,955 shares of company stock worth $2,583,643. Company insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2017/12/16/dexcom-dxcm-earning-somewhat-favorable-news-coverage-analysis-finds.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply